Skip to main content
NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.89%ABBV+0.39%CSCO-2.13%1398.HK-0.69%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.47%UNH-1.34%3988.HK+1.12%0005.HK+1.80%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.96%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.58%EURAUD-0.53%EURCAD-0.51%CADCHF+0.47%AUDJPY+0.46%USDTRY+0.43%GBPTRY+0.41%CADJPY+0.39%USDZAR-0.35%GBPAUD-0.33%GBPHKD+0.32%EURNZD-0.31%AUDUSD+0.30%NZDCHF+0.29%GBPMXN-0.28%USDCAD-0.27%GBPCAD-0.27%GBPZAR-0.27%EURGBP-0.23%NOKJPY+0.23%EURUSD-0.23%EURZAR-0.22%AUDNZD+0.22%NZDJPY+0.21%PLNJPY+0.21%USDCHF+0.19%GBPCHF+0.19%NZDSGD+0.19%NZDCAD-0.18%SGDJPY+0.18%NZDMXN+0.18%USDSEK-0.16%AUDSGD+0.16%USDILS+0.16%USDNOK-0.14%USDDKK-0.14%EURJPY-0.13%USDJPY+0.12%EURHKD+0.12%USDPLN-0.12%GBPJPY+0.11%AUDDKK+0.10%AUDNOK+0.10%USDCNH-0.10%USDMXN-0.09%NZDUSD+0.09%GBPNZD-0.08%CHFSGD+0.08%USDSGD-0.08%CHFJPY-0.08%EURSGD+0.05%EURCHF-0.05%EURCNH+0.05%USDCOP-0.04%EURSEK-0.04%EURCZK+0.03%USDTHB+0.03%AUDCAD+0.02%CHFNOK+0.02%EURNOK-0.01%EURPLN+0.01%EURDKK-0.01%CHFSEK-0.01%USDHKD+0.01%GBPSGD+0.01%GBPUSD+0.01%XPTUSD+2.03%XAGUSD+1.70%GAGUSD+1.69%HG1+1.45%UKOIL-1.14%GAUUSD+1.11%XAUUSD+1.11%USOIL-0.98%S1+0.72%COTTON+0.51%C1+0.45%W1+0.35%BTCUSD-1.05%ETHUSD+11.79%USDTUSD-0.04%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.94%ZECUSDT-8.05%DOGEUSD+5.25%XMRUSDT-2.43%LINKUSD+7.35%XLMUSD-2.87%BCHUSDT-7.09%LTCUSD+1.20%UNIUSD-6.85%SUIUSD-6.34%HBARUSDT-1.58%TONUSD+18.86%TAOUSDT-6.00%AAVEUSD-4.66%DOTUSDT+2.92%ICPUSDT-6.67%ONDOUSDT+1.32%WLDUSDT-6.00%JUPUSDT-2.55%ARBUSDT-4.96%ATOMUSDT+7.56%STXUSDT+6.42%INJUSDT-6.84%FETUSDT-3.97%PYTHUSDT+12.53%TIAUSDT+9.73%SEIUSDT-3.41%IMXUSDT+7.40%GRTUSDT-3.83%OPUSDT-0.41%WIFUSDT-8.72%IOTAUSDT-5.47%AXSUSDT-5.55%POLUSDT-2.78%FARTCOINUSDT+1.82%EOSUSDT-0.39%DYDXUSDT-0.31%GALAUSDT-4.26%ORDIUSDT-6.31%RONINUSDT-4.25%NOTUSDT-4.76%NVDA+0.14%AAPL+0.02%GOOGL-0.63%MSFT-0.03%AMZN+0.24%TSM-3.01%SPCX-4.19%META-0.23%AVGO-4.35%TSLA-0.03%SKHY-4.35%MU+0.17%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%0700.HK+1.89%ABBV+0.39%CSCO-2.13%1398.HK-0.69%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%1816.HK-26.47%UNH-1.34%3988.HK+1.12%0005.HK+1.80%GE+0.66%HSBA.L-1.95%PM+4.05%0857.HK+0.20%0939.HK+0.96%NFLX+2.68%MS-1.20%HD+3.39%AUDCHF+0.58%EURAUD-0.53%EURCAD-0.51%CADCHF+0.47%AUDJPY+0.46%USDTRY+0.43%GBPTRY+0.41%CADJPY+0.39%USDZAR-0.35%GBPAUD-0.33%GBPHKD+0.32%EURNZD-0.31%AUDUSD+0.30%NZDCHF+0.29%GBPMXN-0.28%USDCAD-0.27%GBPCAD-0.27%GBPZAR-0.27%EURGBP-0.23%NOKJPY+0.23%EURUSD-0.23%EURZAR-0.22%AUDNZD+0.22%NZDJPY+0.21%PLNJPY+0.21%USDCHF+0.19%GBPCHF+0.19%NZDSGD+0.19%NZDCAD-0.18%SGDJPY+0.18%NZDMXN+0.18%USDSEK-0.16%AUDSGD+0.16%USDILS+0.16%USDNOK-0.14%USDDKK-0.14%EURJPY-0.13%USDJPY+0.12%EURHKD+0.12%USDPLN-0.12%GBPJPY+0.11%AUDDKK+0.10%AUDNOK+0.10%USDCNH-0.10%USDMXN-0.09%NZDUSD+0.09%GBPNZD-0.08%CHFSGD+0.08%USDSGD-0.08%CHFJPY-0.08%EURSGD+0.05%EURCHF-0.05%EURCNH+0.05%USDCOP-0.04%EURSEK-0.04%EURCZK+0.03%USDTHB+0.03%AUDCAD+0.02%CHFNOK+0.02%EURNOK-0.01%EURPLN+0.01%EURDKK-0.01%CHFSEK-0.01%USDHKD+0.01%GBPSGD+0.01%GBPUSD+0.01%XPTUSD+2.03%XAGUSD+1.70%GAGUSD+1.69%HG1+1.45%UKOIL-1.14%GAUUSD+1.11%XAUUSD+1.11%USOIL-0.98%S1+0.72%COTTON+0.51%C1+0.45%W1+0.35%BTCUSD-1.05%ETHUSD+11.79%USDTUSD-0.04%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.94%ZECUSDT-8.05%DOGEUSD+5.25%XMRUSDT-2.43%LINKUSD+7.35%XLMUSD-2.87%BCHUSDT-7.09%LTCUSD+1.20%UNIUSD-6.85%SUIUSD-6.34%HBARUSDT-1.58%TONUSD+18.86%TAOUSDT-6.00%AAVEUSD-4.66%DOTUSDT+2.92%ICPUSDT-6.67%ONDOUSDT+1.32%WLDUSDT-6.00%JUPUSDT-2.55%ARBUSDT-4.96%ATOMUSDT+7.56%STXUSDT+6.42%INJUSDT-6.84%FETUSDT-3.97%PYTHUSDT+12.53%TIAUSDT+9.73%SEIUSDT-3.41%IMXUSDT+7.40%GRTUSDT-3.83%OPUSDT-0.41%WIFUSDT-8.72%IOTAUSDT-5.47%AXSUSDT-5.55%POLUSDT-2.78%FARTCOINUSDT+1.82%EOSUSDT-0.39%DYDXUSDT-0.31%GALAUSDT-4.26%ORDIUSDT-6.31%RONINUSDT-4.25%NOTUSDT-4.76%
KS

Kodiak Sciences Inc. (KOD)

NASDAQ • Healthcare

$94.26
+$3.18 (+3.5%)
Market closed

Last close at October 8, 2026 at 20:00 UTC

Open$90.01
Day Range$89.54 - $94.95
Avg. Volume (3M)3.6M
Market Cap$5.8B
52 Week Range
$10.94$104
Next EarningsIn 34 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$241.9M
EPS (TTM)
-$4.19
ROA (TTM)
-94.23%
Current Ratio
2.49

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-2.0%Q1 2026-$1.04
-1.1%Q2 2026-$0.94
-9.8%Q3 2026-$1.05
Next

Nov 12

in 34 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -9.8%

Kodiak Sciences’ preliminary results for the second fiscal quarter of 2026 showed EPS trailing consensus, with -$1.05 against the -$0.96 estimate (difference -$0.09), as the clinical-stage retinal-disease developer continued to post losses; the company reported the quarter on August 12, 2026. GAAP net income was a loss of about $65.6 million, down -20.9% year over year from a loss of about $54.3 million, while operating income came in at a loss of roughly $66.8 million. Operating cash flow was negative at about $46.2 million. On a year-over-year basis, EPS of -$1.05 compared with -$1.03 a year ago (down -1.9%). For the next period, consensus calls for EPS of -$0.99.

View full earnings history

About Kodiak Sciences Inc.

Kodiak Sciences Inc. is a clinical-stage Biotechnology company listed on NASDAQ under KOD that focuses on treatments for retinal disease. The company is dedicated to discovering, advancing, and bringing to market therapies for conditions affecting the retina, and it remains in the clinical development phase.

Name
Kodiak Sciences Inc.
CEO
Victor Perlroth
Website
kodiak.com
Industry
Healthcare
Year Founded
2009
Employees
141

Today's Snapshot

AI-generated

KOD closed 3.5% above yesterday's close, while its sector was flat. Volume was about a quarter of its usual level. Kodiak Sciences announced plans to present late-stage trial data for its eye-drug candidates at AAO 2026.

Trading Volume

Below 10d avg (6.6M)

1.5M

vs S&P 500 Today

Strong Outperformance

+4.03%

Updated: October 8, 2026 at 20:26 UTC

Technical Indicators

6 Buy0 Neutral2 Sell
KOD is showing a strong technical bid as price sits well above short-, intermediate- and long-term moving averages while ADX indicates a powerful trend. Momentum measures and MACD confirm upside bias even as multiple oscillators read overbought, suggesting strength rather than weakness. Volume-based OBV is strongly positive and the classic pivot sits under the market, reinforcing near-term support. Volatility is elevated, with average true range noticeable versus the share price, which tempers the momentum readings. Technical takeaway: Strong Buy.
All signals
  • EMA (5 indicators)$37.71 - $83.48
    Buy
  • RSI (14)81.39
    Sell
  • Stochastic %K (14, 3, 3)84.58
    Sell
  • MACD Level (12, 26)15.84
    Buy

Peers & Related Assets

REGNRegeneron Pharmaceuticals, Inc.
$739.57-0.3%
OCULOcular Therapeutix, Inc.
$7.51+3.9%
FDMT4D Molecular Therapeutics, Inc.
$12.7+0.9%
EYPTEyePoint Pharmaceuticals, Inc.
$3.46+4.2%
BLCOBausch + Lomb Corporation
BLTEBelite Bio, Inc
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.